BCL2 and acute myeloid leukemia: It is assumed that the cause of this resistance lies in the lack of therapeutic target i.e. BCL2, since leukemic cells belonging to these AML subtypes originate from more differentiated hematopoietic cells, having lower, or non-existent BCL2 expression.39,40